Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic effects of growth hormone treatment in children with GHD or SGA
NL-OMON36604Not yet recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of somatropin in growth hormone deficiency (GHD) and Short stature in children born small for gestational age (2 cohorts), sponsored by Maastricht University Medical Center+. Primary endpoint: Metabolic change at 6 weeks. Planned start Jul 2011; status: not yet recruiting.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)Short stature in children born small for gestational age
Beyond the preview
Go deeper on NL-OMON36604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36604.